Massachusetts — A recent study indicates that a nasal spray designed to mitigate neuroinflammation may provide a novel therapeutic approach for traumatic brain injury (TBI) victims. Researchers at Mass General Brigham have observed that the spray, containing anti-CD3 antibodies, reduced central nervous system damage and behavioral deficits in mouse models.
Findings published in Nature Neuroscience detail the examination of Foralumab, a monoclonal antibody. The study, led by Dr. Saef Izzy, explored the communication between regulatory cells induced by nasal treatment and microglial immune cells. The results demonstrated that modulating the neuroinflammatory response correlated with improved neurological outcomes, including reduced anxiety and cognitive decline, alongside enhanced motor skills.
Dr. Izzy expressed that effective treatments for the prevention of long-term traumatic brain injury effects are not presently available. The research team conducted multiple experiments on mice with moderate to severe TBI, revealing how the nasal spray influenced immune responses.
Dr. Howard Weiner, a senior author of the study, highlighted the potential for this treatment in various brain injuries, including intracerebral hemorrhage and stroke. Future steps involve translating the preclinical findings to human trials. Researchers envision the nasal spray being administered rapidly following a TBI, potentially even on sports fields.
If you or a loved one has experienced a traumatic brain injury due to an accident, understanding your legal options is crucial. Contact us today for information regarding your rights and potential compensation. We offer free consultation to discuss your case.
